CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will present at the Cowen and Company 37th
Annual Health Care Conference on Wednesday, March 8, 2017, at 8:00 a.m.
ET. The conference will be held at the Boston Marriott Copley Place in
A live webcast of the presentation can be accessed on the Investors &
Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery and development of innovative RNAi-based therapeutics for
diseases involving the liver, including rare diseases, chronic liver
diseases, cardiovascular diseases, and viral infectious diseases. The
Company is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners. For more information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006379/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media